Research identifies the human transferrin receptor as an alternative pathway for SARS-CoV-2 infection, offering potential new targets for COVID-19 therapies.
SARS-CoV-2 infection linked to increased benign prostatic hyperplasia (BPH) complications and medication use. Urological manifestations in COVID-19 patients emphasize the importance of awareness among clinicians.
Researchers from the University of Texas Southwestern have developed an aerosolized, mutated form of ACE2 that effectively neutralizes various SARS-CoV-2 variants in both cell cultures and mice. The study suggests that this modified ACE2 has promising preventive and therapeutic potential against COVID-19, especially with its easy aerosolized administration.